Drugs / Id-KLH Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00001572 | Jan 1997 → Jul 1999 | follicular lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Id-KLH Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001572 ↗ |
| Modality | Vaccine | “a vaccine consisting of 0.5 mg autologous tumor-derived immunoglobulin (Id) conjugated to KLH” NCT00001572 ↗ |
| Route | Subcutaneous | “The vaccine is administered with subcutaneous QS-21 as an immunological adjuvant.” NCT00001572 ↗ |